(PNP) deficiency is associated with a severe defect in thvmnus-derived (T)-lymphocyte function comlbinied with normal bone marrow-derived (B)-lvmphocvte ftinction. To investigate the role of this enzvme deficiency in the resulting immune dysfunction, wve mleastured the levels of ribonucleoside and deoxvriboniucleoside triphosphates in erythrocvtes from twvo unirelated PNP-deficient, T-lymphocvte-deficient patients. Both PNP-deficient patients have abnormally high levels of deoxyguanosine triphosphate (deoxy-GTP) in their erythrocytes (5 and 8 nmol/ml packed ervthrocvtes). In contrast, normal controls and adenosinie deaminase-deficient, immunodeficient patients do not have detectable amounts of deoxvGTP (<0.5 nmol/nml packed erythrocytes). We propose that deoxvguanosine, a substrate of PNP. is the potentially lvImphotoxic metabolite in PNP deficiency. The mechanismii of toxicitv involves phosphorvlation of Dr.
INTRODUCTION
Deficiencies in either adenosine deamliinase (ADA)' or purinie nucleoside phosphorylase (PNP), two enzymnes wvhich act sequentially in the purine salvage pathway ( Fig. 1 ), are associated with immunodeficiencv diseases (1, 2) . WVhereas ADA deficiency results in combined bone marrow-derived (B)-anid thvmusderived (T)-lvmphocvte deficienicy, PNP-deficient patients exhibit T-cell dysfunction with normiial Blymphocyte function. WVhile there are a number of proposed mechanismiis to explain the associationi of lymphotoxicitv with ADA deficiency (3) (4) (5) (6) (7) , the cauise of the T-cell deficiency associated with the absenice of PNP activity has received less attenitioni. It was postulated that an accumulationi of the PNP substrate, inosine, inhibited ADA activity cauising finietional ADA deficiency (8) . Subseqiuenitly, orotic aciduria wvas f0und in two PNP-deficienit patients, 'Abbreviationis used in this paper: ADA, adenosinc deamiiniase; deox\vATP, deoxyadenosine triphosphate; deoxy-CTP, deoxveytidine triphosphate; deoxyGTP, deoxyguanosinle triphosphate; GTP, guanosinie triphlosphate; HGPRT, hvpoxanthine-guanine phosphoribosyl tranisferase; HPLC, high-performance li(qtuid chromatography; PNP, purine nuicleoside phosphorvlase. indicatinig that pyrimidine starvation imiight exist in some of the tissues of the patients (9). However, oral uridine therapy did not significantly improve their immune funletion but did eliminate the orotic aciduria (9) . Recently, strikingly high levels of' deoxyadeniosine triphosphate (deoxyATP) were found in erythrocytes from several ADA-deficient, immunodeficient patients (10) . Since deoxyATP is a known inhibitor of ribonucleotide reductase (11), it was suggested that an aecumuilation of deoxyATP in the patients' lymphocytes is the cause of the immunodeficiency in ADAdeficient childreni (10) .
Deoxyguanosine is one of' the four PNP substrates which accumulate in the urine of PNP-deficient children (12) . Human lymphocytes are capable of' phosphorylating deoxyguanosine to deoxyguanosine triphosphate (deoxyGTP) (13) , which like deoxyATP can inhibit mammalian ribonucleotide reduetase (11 (14) , with inherited deficiencies of PNP have been previously described. The ADA-deficient child with combined B-and T-lymphocyte deficiency has also been described previously (10) as has the adult male deficient in erythrocyte hypoxanthine-guanine phosphoribosyl transferase (HGPRT) (12) . The control subjects included normal children and adults and two immunodeficient children. One immunodeficient child has a severe combined immunodeficiency while the other has only a Tlymphocyte deficiency, but both children have normal activities of ADA and PNP in their erythrocytes. None of the imimunwiio(leficient patients ha(I b)een transftiused (r was reeeix i ug (Irligs l)efore study.
Preparatiooi oj' samlies. Whole I)100() (2-:3 ml) \was withdrawn fromil pIatienits inito lhepariniize(l s\ ringes aod promptly cenitriflugerl (10,000 g for 2 imin) at ambient teml)erature. The p)lasma was removed, ain(l an eual volume of ice-coldc _2 N perehlioric acid was added to the erythrocyte pellet. The chilled mixttire was againl cenltrifugedl (10,000 g for 2 min) to remove the precipitated proteini, and the stiperinate was neuitralizedl to pH 6 to 8 with .5 N KOH, to precipitate potassitiuim perchiorate. After chillinlg on ice, the supernatant soluitionis were centrifuiged to remove the l)otassiun perchiorate, frozeni, anid \when niee cssary, shiippe(d to Sani Franciseo, Calif for analysis.
Highi performnatice li(u/nid chromlatogra phyp. High performance li(juiid chromatography was performed uitilizing an Altex miieteriing system with a 20-,il UV analyzer (Altex Scientific Inc., Berkeley, Calif:), as described previously (10) .
Eitzi)lmatic detern iiniationi of deoxyGTP. The concentration of deoxyGTP in erythrocyte extracts was determiinled by the method of' Solter and Handschumacher (15) 
RESULTS
The levels of nucleoside triphosphates in erythrocyte extracts from ADA-and PNP-deficient patients, and from normiial controls, were determined with highperformiiance liquid chromatography (HPLC). Erythrocytes from PNP-deficient patients contain a significant amount of deoxyGTP, which is not present in erythrocytes from either normal controls or ADA-deficienit patienits (Fig. 2) . In contrast, erythrocytes from ADAdeficient patients contain deoxyATP, whiclh is not presenit in either normal controls or PNP-deficienit erythrocytes (10) (Fig. 2) .
The concentrations of nucleoside triphosphates in erythrocytes from normal controls, ADA-deficienit, PNP-deficienit, and HGPRT-deficient patients are summarized in Table I . deoxyGTP levels are more than 10-fold higher in erythrocyte extracts from the two PNP-deficient patients, compared to the other controls and patients. While the ATP levels of all the extracts tested are comparable, guanosine triphosphate (GTP) concentrations are two-four times lower in extracts from either PNP-deficient or HGPRT-deficient patients, compared to normal controls. This decrease in GTP concentration is presumably the result of impaired guanine salvage capability caused by the absence of either PNP or HGPRT; however, other mechanisms are certainly possible.
To confirm the presence of deoxyGTP in PNPdeficient erythrocytes, we assayed deoxyGTP in the GTP NORMAL dGTP PNP/-ADA/- The values were determined by high-performance liquid chromatography as described in the legend to Fig. 1 extracts from both PNP-deficient patients and normal controls with the DNA-dependent DNA polymerase reaction (15) . The results obtained by HPLC and by the DNA polymerase assay agree. The control extracts contain deoxyGTP at a concentration of less than 0.5 nmol/ml of packed erythrocytes, but the erythrocytes from PNP-deficient patients 1 and 2 contained 7 and 10 nmol of deoxyGTP/ml of packed erythrocytes, respectively, by the DNA polymerase assay.
DISCUSSION
deoxyGTP is synthesized in mammalian cells either via the reduction of guanosine diphosphate by ribonucleotide reductase (11) , or by phosphorylation of deoxyguanosine (16) . Since nondividing cells do not have ribonucleotide reductase activity (17), the phosphorylation route is the source of deoxyGTP in the erythrocytes from PNP-deficient patients. PNP-deficient patients cannot degrade deoxyguanosine, and thus, deoxyguanosine can either be phosphorylated to deoxyGTP or secreted in the urine of these pa- It is conceivable that abnormally high levels of deoxyGTP accumulate in the T lymphocytes of PNPdeficient children and cause the observed T-lymphocyte killing. Since T lymphocytes are absent in PNPdeficient patients, it is not possible to measure deoxy-GTP pools directly in these cells. However, it is intriguing that the thymus has the highest activity of deoxycytidine kinase (18) , which also phosphorylates deoxyguanosine (16) .2 Moreover, of the human fetal tissues examined by Carson et al., the thymus and spleen exhibit the highest deoxyguanosine phosphorylating activity (19) . Thus, in the PNP-deficient patients, these tissues would be expected to have even higher deoxyGTP levels than do their erythrocytes. These observations can explain the tissue specificity of PNP deficiency because elevated deoxyGTP levels and the resulting cytotoxicity should correlate with deoxyguanosine phosphorylation.
This hypothesis also explains the clinical similarities in the ADA-and PNP-deficient, immunodeficient patients; a deficiency in ADA results in failure to degrade deoxyadenosine which is then phosphorylated to deoxyATP (10, 13) , and a deficiency in PNP leads to an accumulation of deoxyguanosine which is phosphorylated to deoxyGTP (13, 16) . In both types of enzyme deficiencies, the accumulation of the phosphorylated deoxyribonucleoside could cause the inhibition of ribonucleotide reductase, subsequent deoxynucleoside triphosphate starvation, and inhibition of DNA synthesis. The differences in the phenotypes of ADA-and PNP-deficient patients may be understood when more is known about the tissue distributions of specific kinase activities.
Finally, human lymphoid tissues can phosphorylate all four deoxynucleosides (13) . Thus, a possible therapy for both ADA and PNP deficiencies would be ad- 2 Gudas, L. J., B. Ullman, A. Cohen, and D. W. Martin, Jr. 1978. Deoxyguanosine toxicity in cultured lymphocytes and its relationship to purine nucleoside deficiency and the associated immunodeficiency disease. Submitted for publication. ministration of the deoxynucleosides, particularly deoxycytidine, the triphosphates of which are depleted in these tissues. Deoxycytidine is not toxic in a number of model systems,2 and in fact, deoxyCTP does not appear to play a role in the allosteric regulation of ribonucleotide reductase (11, 20) .
